IS6894A - Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda - Google Patents

Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda

Info

Publication number
IS6894A
IS6894A IS6894A IS6894A IS6894A IS 6894 A IS6894 A IS 6894A IS 6894 A IS6894 A IS 6894A IS 6894 A IS6894 A IS 6894A IS 6894 A IS6894 A IS 6894A
Authority
IS
Iceland
Prior art keywords
threatening
treat
methods
binding agents
skin disorders
Prior art date
Application number
IS6894A
Other languages
English (en)
Inventor
K. Vaishnaw Akshay
D. Cooper Kevin
Shrager Daniel
S. Mcgormick Thomas
Original Assignee
Biogen, Inc.
University Hospitals Of Cleveland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., University Hospitals Of Cleveland filed Critical Biogen, Inc.
Publication of IS6894A publication Critical patent/IS6894A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6894A 2001-02-01 2003-07-25 Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda IS6894A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26596401P 2001-02-01 2001-02-01
PCT/US2002/002314 WO2002060480A1 (en) 2001-02-01 2002-01-25 Methods for treating or preventing skin disorders using cd2-binding agents

Publications (1)

Publication Number Publication Date
IS6894A true IS6894A (is) 2003-07-25

Family

ID=23012611

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6894A IS6894A (is) 2001-02-01 2003-07-25 Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda

Country Status (22)

Country Link
US (3) US20040170635A1 (is)
EP (1) EP1409015A4 (is)
JP (1) JP2004527477A (is)
KR (1) KR20040043112A (is)
CN (1) CN1527723A (is)
AR (1) AR035079A1 (is)
BG (1) BG108020A (is)
BR (1) BR0206905A (is)
CA (1) CA2436411A1 (is)
CZ (1) CZ20032081A3 (is)
EA (1) EA200300849A1 (is)
EE (1) EE200300366A (is)
GE (1) GEP20063828B (is)
HU (1) HUP0303826A2 (is)
IS (1) IS6894A (is)
MX (1) MXPA03006919A (is)
NO (1) NO20033443L (is)
PL (1) PL368556A1 (is)
SK (1) SK9722003A3 (is)
WO (1) WO2002060480A1 (is)
YU (1) YU61203A (is)
ZA (1) ZA200305936B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2252999T3 (es) * 1998-08-31 2006-05-16 Biogen Idec Ma Inc. Modulacion de celulas t efectoras y de memoria con un ligando de cd2.
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2002320352A1 (en) 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
DE60326370D1 (de) 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
US20080020383A1 (en) * 2004-05-04 2008-01-24 Genaissance Pharmaceuticals, Inc. Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment
EP1750747A1 (en) * 2004-05-07 2007-02-14 Astellas US LLC Soluble lfa-3 polypeptide for treating viral disorders
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
US9289469B2 (en) 2009-09-10 2016-03-22 Mayo Foundation For Medical Education And Research Depleting immunosuppressive monocytes within a mammal
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014078272A1 (en) 2012-11-13 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
WO2014182761A1 (en) 2013-05-09 2014-11-13 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
WO2024050455A2 (en) * 2022-08-31 2024-03-07 Heitmeyer Jamie Nicole Anti-rhd antibodies for treating inflammatory dermal condition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2112335T3 (es) * 1991-10-07 1998-04-01 Biogen Inc Procedimiento profilactico o terapeutico de enfermedades de la piel causadas por celulas que presentan antigenos por medio de inhibidores de la interaccion entre cd2 y lfa-3.
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
ES2252999T3 (es) * 1998-08-31 2006-05-16 Biogen Idec Ma Inc. Modulacion de celulas t efectoras y de memoria con un ligando de cd2.

Also Published As

Publication number Publication date
US20040170635A1 (en) 2004-09-02
CN1527723A (zh) 2004-09-08
CA2436411A1 (en) 2002-08-08
JP2004527477A (ja) 2004-09-09
EP1409015A1 (en) 2004-04-21
YU61203A (sh) 2006-05-25
PL368556A1 (en) 2005-04-04
NO20033443D0 (no) 2003-08-01
BG108020A (bg) 2004-03-31
GEP20063828B (en) 2006-05-10
HUP0303826A2 (hu) 2004-03-01
MXPA03006919A (es) 2004-06-02
WO2002060480A1 (en) 2002-08-08
EP1409015A4 (en) 2006-04-12
BR0206905A (pt) 2004-07-06
US20030185824A1 (en) 2003-10-02
NO20033443L (no) 2003-09-30
ZA200305936B (en) 2005-01-26
US20070031443A1 (en) 2007-02-08
CZ20032081A3 (cs) 2004-01-14
SK9722003A3 (en) 2004-05-04
AR035079A1 (es) 2004-04-14
WO2002060480A9 (en) 2004-05-27
KR20040043112A (ko) 2004-05-22
EA200300849A1 (ru) 2004-02-26
EE200300366A (et) 2003-12-15

Similar Documents

Publication Publication Date Title
IS6894A (is) Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda
IS8023A (is) Samsett meðferð til að meðhöndla ónæmisbólgusjúkdóma
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
IS6816A (is) Aðferðir til að meðhöndla p38 kínasa tengda sjúkdóma og pýrrólótríazín sambönd, sem gagnleg eru semkínasa hindrar
HK1089364A1 (en) Topical compositions and methods for treating pain
IS8371A (is) Notkun breyttra sýklósporína til að meðhöndla HCVsjúkdóma
EP1575513A4 (en) COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
AU2002234192A8 (en) Methods and transdermal compositions for pain relief
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
DK1423102T3 (da) Plaster til behandling af neglevæksts dysfunktioner og lidelser
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
EP1565136A4 (en) COMPOSITIONS AND METHODS FOR TRANSDERMAL OXYBUTYNINE THERAPY
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EP1503751A4 (en) THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IS7417A (is) Ambroxól til að meðhöndla kvalafullt ástand í munni og koki
IS6870A (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og notkun þeirra í meðferð
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
EE200300582A (et) IL-18 inhibiitorite kasutamine kesknärvisüsteemi kahjustuste raviks või ennetamiseks
EP1546377A4 (en) METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISORDERS USING MOLECULES 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 OR 13424